| Literature DB >> 29410886 |
Diego M Carrion1, Sergio Alonso Y Gregorio2, Juan Gómez Rivas1, Alfredo Aguilera Bazán1, Jesús Díez Sebastián3, Luis Martínez-Piñeiro1.
Abstract
INTRODUCTION: Nephron-sparing surgery is currently the treatment of choice for renal cell carcinoma stage T1a. During the past years, several hemostatic agents (HA) have been developed in order to reduce surgical complications. We present the results of our series and the impact of the use of HA in the prevention of surgical complications in laparoscopic partial nephrectomies (LPNs).Entities:
Keywords: hemostatic agents; laparoscopic; partial nephrectomy; renal cell carcinoma
Year: 2017 PMID: 29410886 PMCID: PMC5791400 DOI: 10.5173/ceju.2017.1432
Source DB: PubMed Journal: Cent European J Urol ISSN: 2080-4806
Demographics, perioperative data, and follow up of the entire cohort (n = 77)
| n (%, ±) | |
|---|---|
| Median age, years (±sd) | 57.17 (±12.1) |
| Male / Female | 56 (72.7%) / 21 (27.3%) |
| Comorbidities, n | |
| Hypertension | 26 (33.8%) |
| Diabetes Mellitus | 14 (18.2%) |
| Ischemic cardiopathy | 4 (5.2%) |
| COPD | 4 (5.2%) |
| Previous abdominal surgery | 29 (37.6%) |
| Radiological tumor location | |
| Upper pole | 20 (26%) |
| Middle aspect | 27 (35.1%) |
| Lower pole | 30 (38.9%) |
| Right side | 45 (58.4%) |
| Left side | 32 (41.6%) |
| Radiological tumor size | |
| Mean diameter, cm (±sd) | 2.91 (±0.99) |
| ≤4 | 67 (87%) |
| >4 cm | 10 (13%) |
| Mean hemoglobin, g/dl ±sd) | |
| Pre-operative | 14.59 ±1.49 |
| Post-operative, day 1 | 12.25 ±1.62 |
| Mean serum creatinine, mg/dl (±sd) | |
| Pre-operative | 0.98 ±0.21 |
| Post-operative, 1 month | 1.14 ±0.37 |
| Mean ischemia time, min ±sd) | 27.7 ±6.7 |
| Suturing of the collecting system, n | 31 (40.2%) |
| Perioperative blood transfusion, n | 7 (9.1%) |
| Urinary leakage | 5 (6.5%) |
| Acute renal failure | 5 (6.5%) |
| Infection (any) | 2 (2.6%) |
| Histology | |
| Renal cell carcinoma | 61 (79.2%) |
| Oncocytoma | 11 (14.3%) |
| Angiomyolipoma | 3 (3.9%) |
| Renal papillary adenoma | 1 (1.3%) |
| Metastasis | 1 (1.3%) |
| Pathological stage (out of 61 RCC) | |
| pT1a | 48 (78.7%) |
| pT1b | 5 (8.2%) |
| pT3a | 8 (13.1%) |
| Positive margins, n | 9 (14.7%) |
| Mean hospital stay, days (±sd) | 4.85 ±3.6 |
| Mean follow-up, months | 31.4 ±23.2 |
Comparison of patients according to intraoperative use of hemostatic agents. No difference was found in any of the comparisons mentioned (p >0.05 for all)
| No use of HA (GROUP A) | Use of HA (GROUP B) | |
|---|---|---|
| Number of patients, n | 41 (53.2%) | 36 (46.8%) |
| Median age, years (± sd) | 58.6 ±12.2) | 56.27 (±11.8) |
| Prior abdominal surgery, n | 18 (43.9%) | 11 (30.5%) |
| Gender, male | 30 (73.2%) | 26 (72.2%) |
| Radiological tumor size | ||
| ≤4 cm | 33 (80.5%) | 32 (88.9%) |
| >4 cm | 8 (19.5%) | 4 (11.1%) |
| Radiological tumor location, n | ||
| Upper pole | 11 (26.8%) | 9 (25%) |
| Middle aspect | 16 (39%) | 11 (30.5%) |
| Lower pole | 14 (34.2%) | 16 (44.5%) |
| Right | 26 (63.4%) | 19 (52.8%) |
| Left | 15 (36.6%) | 17 (47.2%) |
| Endophytic pattern | 21 (51.2%) | 17 (47.2%) |
| Exophytic pattern | 20 (48.8%) | 19 (52.8%) |
| Mean serum creatinine, mg/dl (±sd) | ||
| Pre-operative | 1.01 (±0.21) | 0.95 (±0.22) |
| Post-operative, 1 month | 1.09 (0.31) | 1.12 (±0.41) |
| Mean hemoglobin, g/dl (±sd) | ||
| Pre-operative | 14.56 (±1.66) | 14.52 (±1.25) |
| Post-operative | 12.55 (±1.67) | 12.39 (±1.39) |
| Mean ischemia time, min (± sd) | 26.68 (±6.9) | 28 (±6.4) |
| Suturing of the collecting system, n | 18 (43.9%) | 13 (36.11%) |
| Histology | ||
| Renal cell carcinoma | 30 (73.2%) | 31 (86.1%) |
| Oncocytoma | 7 (17.1%) | 4 (11.1%) |
| Angiomyolipoma | 2 (4.9%) | 1 (2.8%) |
| Renal papillary adenoma | 1 (2.4%) | 0 |
| Metastasis | 1 (2.4%) | 0 |
| Post-operative complications, n | ||
| Clavien-Dindo I | 1 (2.43%) | 2 (5.5%) |
| Clavien-Dindo II | 6 (14.6%) | 4 (11.1%) |
| Clavien-Dindo III | 2 (4.8%) | 2 (5.5%) |
| Perioperative blood transfusion | 3 (7.3%) | 4 (11.1%) |
| Urinary leakage / fistula | 3 (7.3%) | 2 (5.5%) |